BCI Pharma develops innovative research programs to deliver novel, highly potent and selective kinase inhibitors. The research programs focus on high unmet medical needs with the ultimate aim to improve patients’ life.
Thanks to its high-performance platforms, BCI Pharma has already identified a preclinical candidate for the treatment of peripheral neuropathic pain and psoriasis. BCI Pharma also intends to deliver drugs for inflammatory diseases, CNS disorders and cancer.